Literature DB >> 19566588

Gastric slow waves, gastrointestinal symptoms and peptides in systemic sclerosis patients.

T A McNearney1, H S Sallam, S E Hunnicutt, D Doshi, D E Wollaston, M D Mayes, J D Z Chen.   

Abstract

Impaired gastric slow waves, frequent gastrointestinal (GI) symptoms and altered GI peptides have been reported in Scleroderma (SSc) patients. The aim of this study was to investigate the associations among these three important components in GI dysmotility. Seventeen fasted SSc patients underwent four channel surface electrogastrography, measuring % of normal gastric slow waves or dysrhythmia. Patients completed a questionnaire designed by us to assess demographics, upper and lower GI symptoms (symptom presence, frequency and impact on quality of life, QOL), by YES/NO, Likert Scales and Visual Analogue Scales 1-100 mm (called GI Dysmotility Questionnaire, GIDQ) and health-related QOL by SF-36. Fasting plasma vasoactive intestinal peptide (VIP) and motilin levels were measured by peptide immunoassays. There were significant correlations between percentages of gastric dysrhythmias (bradygastria or arrhythmia) and a number of major GI symptoms such as nausea, abdominal bloating and pain. The plasma level of VIP was correlated positively with % dysrhythmia but negatively with % normal slow waves. Motilin was positively correlated with slow wave coupling (coordination). No major differences were noted in the measured peptides or gastric slow waves between limited SSc and diffuse SSc. Correlations were noted between SF-36 domain scores and our GIDQ scores. In SSc patients, gastric dysrhythmias are correlated with certain GI symptoms. Correlations are also noted between plasma VIP/Motilin levels and gastric slow waves. Thus in SSc, gastric dysrhythmias may be predictive of development of certain dyspeptic symptoms. Plasma VIP may be involved in the development of dysrhythmias.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19566588      PMCID: PMC3176740          DOI: 10.1111/j.1365-2982.2009.01350.x

Source DB:  PubMed          Journal:  Neurogastroenterol Motil        ISSN: 1350-1925            Impact factor:   3.598


  49 in total

Review 1.  Assessment of disease severity and prognosis.

Authors:  T A Medsger; S Bombardieri; L Czirjak; R Scorza; A Della Rossa; W Bencivelli
Journal:  Clin Exp Rheumatol       Date:  2003       Impact factor: 4.473

2.  The association of antinuclear antibodies with organ involvement and survival in systemic sclerosis.

Authors:  R Hesselstrand; A Scheja; G Q Shen; A Wiik; A Akesson
Journal:  Rheumatology (Oxford)       Date:  2003-04       Impact factor: 7.580

3.  [Evaluation of quality of life in patients with systemic sclerosis by administering the SF-36 questionnaire].

Authors:  R Cossutta; S Zeni; A Soldi; P Colombelli; A Belotti Masserini; F Fantini
Journal:  Reumatismo       Date:  2002 Apr-Jun

4.  Nerve growth factor and neuropeptides circulating levels in systemic sclerosis (scleroderma).

Authors:  M Matucci-Cerinic; R Giacomelli; A Pignone; M L Cagnoni; S Generini; R Casale; P Cipriani; A Del Rosso; P Tirassa; Y T Konttinen; B M Kahaleh; P S Fan; M Paoletti; C Marchesi; M Cagnoni; L Aloe
Journal:  Ann Rheum Dis       Date:  2001-05       Impact factor: 19.103

5.  The IBS-36: a new quality of life measure for irritable bowel syndrome.

Authors:  Dianne Groll; Stephen J Vanner; William T Depew; Laurington R DaCosta; Jerome B Simon; Aubrey Groll; Nancy Roblin; William G Paterson
Journal:  Am J Gastroenterol       Date:  2002-04       Impact factor: 10.864

6.  Characterization of gastric myoelectrical rhythms in patients with systemic sclerosis using multichannel surface electrogastrography.

Authors:  Terry McNearney; Xuemei Lin; Jharana Shrestha; Jeffrey Lisse; J D Z Chen
Journal:  Dig Dis Sci       Date:  2002-04       Impact factor: 3.199

7.  Severe organ involvement in systemic sclerosis with diffuse scleroderma.

Authors:  V D Steen; T A Medsger
Journal:  Arthritis Rheum       Date:  2000-11

8.  Gastrointestinal dysmotility in patients with acute pancreatitis.

Authors:  Xingpeng Wang; Zihua Gong; Kai Wu; Bingxian Wang; Yaozong Yuang
Journal:  J Gastroenterol Hepatol       Date:  2003-01       Impact factor: 4.029

9.  Survival and causes of death in 366 Hungarian patients with systemic sclerosis.

Authors:  L Czirják; G Kumánovics; C Varjú; Z Nagy; A Pákozdi; Z Szekanecz; G Szucs
Journal:  Ann Rheum Dis       Date:  2007-05-22       Impact factor: 19.103

10.  Immune-mediated neural dysfunction in a murine model of chronic Helicobacter pylori infection.

Authors:  Premysl Bercík; Roberto De Giorgio; Patricia Blennerhassett; Elena F Verdú; Giovanni Barbara; Stephen M Collins
Journal:  Gastroenterology       Date:  2002-10       Impact factor: 22.682

View more
  15 in total

1.  Gastrointestinal Manifestations of Systemic Sclerosis.

Authors:  Andrew B Shreiner; Charles Murray; Christopher Denton; Dinesh Khanna
Journal:  J Scleroderma Relat Disord       Date:  2016-10-18

2.  Beneficial effect of the 5-HT1A receptor agonist buspirone on esophageal dysfunction associated with systemic sclerosis: A pilot study.

Authors:  George P Karamanolis; Stylianos Panopoulos; Anastasios Karlaftis; Konstantinos Denaxas; Dimitrios Kamberoglou; Petros P Sfikakis; Spiros D Ladas
Journal:  United European Gastroenterol J       Date:  2015-06       Impact factor: 4.623

Review 3.  Points to consider for clinical trials of the gastrointestinal tract in systemic sclerosis.

Authors:  Daniel E Furst; Yolanda Braun-Moscovic; Dinesh Khanna
Journal:  Rheumatology (Oxford)       Date:  2017-09-01       Impact factor: 7.580

4.  Initial development of patient-reported instrument assessing harm, efficacy, and misuse of long-term opioid therapy.

Authors:  William C Becker; David A Fiellin; Anne C Black; Carol T Kostovich; Robert D Kerns; Liana Fraenkel
Journal:  J Rehabil Res Dev       Date:  2016

5.  Anorectal motility and sensation abnormalities and its correlation with anorectal symptoms in patients with systemic sclerosis: a preliminary study.

Authors:  Hanaa S Sallam; Terry A McNearney; Jiande Z Chen
Journal:  ISRN Gastroenterol       Date:  2011-06-06

6.  Considerations for a combined index for limited cutaneous systemic sclerosis to support drug development and improve outcomes.

Authors:  Alain Lescoat; Susan L Murphy; David Roofeh; John D Pauling; Michael Hughes; Robert Sandler; François Zimmermann; Rachel Wessel; Whitney Townsend; Lorinda Chung; Christopher P Denton; Peter A Merkel; Virginia Steen; Yannick Allanore; Francesco Del Galdo; Dominique Godard; David Cella; Sue Farrington; Maya H Buch; Dinesh Khanna
Journal:  J Scleroderma Relat Disord       Date:  2020-10-05

7.  The 5-HT1A receptor agonist buspirone improves esophageal motor function and symptoms in systemic sclerosis: a 4-week, open-label trial.

Authors:  George P Karamanolis; Stylianos Panopoulos; Konstantinos Denaxas; Anastasios Karlaftis; Alexandra Zorbala; Dimitrios Kamberoglou; Spiros D Ladas; Petros P Sfikakis
Journal:  Arthritis Res Ther       Date:  2016-09-01       Impact factor: 5.156

8.  Evaluation of electrical activity after vagus nerve-preserving distal gastrectomy using multichannel electrogastrography.

Authors:  Haruaki Murakami; Hideo Matsumoto; Hisako Kubota; Masaharu Higashida; Masafumi Nakamura; Toshihiro Hirai
Journal:  J Smooth Muscle Res       Date:  2013

Review 9.  Electrophysiological Mechanisms of Gastrointestinal Arrhythmogenesis: Lessons from the Heart.

Authors:  Gary Tse; Eric T H Lai; Alex P W Lee; Bryan P Yan; Sunny H Wong
Journal:  Front Physiol       Date:  2016-06-14       Impact factor: 4.566

Review 10.  Current status of multichannel electrogastrography and examples of its use.

Authors:  Haruaki Murakami; Hideo Matsumoto; Daisuke Ueno; Akimasa Kawai; Takaaki Ensako; Yuko Kaida; Toshiya Abe; Hisako Kubota; Masaharu Higashida; Hiroshi Nakashima; Yasuo Oka; Hideo Okumura; Atsushi Tsuruta; Masafumi Nakamura; Toshihiro Hirai
Journal:  J Smooth Muscle Res       Date:  2013
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.